#01

Quotient Therapeutics Secures Financing and Emerges from Stealth Mode

#02

Alto Neuroscience Completes $45 Million Series C Financing

#03

HAN Microbiology Completes Over 100 Million Yuan Pre-A Round Financing

It is reported that, in order to build a drug development platform for living microorganisms, Han Microbiology has established a complete microbial industrialization system from isolation and cultivation, functional screening, mechanism research to application. It has built a library of over 15,000 strains, including the gut microbiota of healthy individuals, the gut microbiota of special populations, a catalog of food-related bacteria, and gene editing of dozens of bacterial strains. By combining functional screening with mechanism research, the team accelerates the drug pipeline process by discovering new functional molecules, new targets, and new circuit mechanisms to identify effector molecules. The companyEstablishedA diversified drug pipeline based on microorganisms and metabolites targeting immune and neural regulation functions, including three drugs for depression and autoimmune diseases, has entered the investigator-initiated clinical research (IIT) stage, with clinical efficacy data expected to be obtained successively next year.。

#04

Novorex Completes $11.5 Billion Series A Financing

November 22nd, AI small molecule drug development company Novorex announced the completion of a 11.5 billion KRW Series A bridge financing.Novorex aims to develop new drugs, including undruggable targets, through drug design that combines biophysical analysis with in vitro/in vivo assays., and accelerate the drug discovery process, reducing the time costs associated with traditional high-throughput screening (HTS) methods. Novorex's fragment-based drug discovery technology (FBDD) can obtain effective substances for target proteins and perform target validation. FBDD searches for small fragment compounds that bind to protein binding sites, then links and optimizes each site to derive substances. This biophysical approach can identify small molecule compounds with weak binding to proteins. Currently, the company is focusing on the fields of oncology and central nervous system diseases, with its lead candidate being an LRRK2 inhibitor for Parkinson's disease, expected to enter preclinical trials next year.

#05

Zeling Biotech Completes Series B Financing

November 24Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as "Zeling Biopharmaceutical") announced that it has successfully completed its Series B financing round recently.The proceeds from this round of financing will be used to advance the Phase 2/3 clinical development of the company's two products and expedite research on the company’s core technology platforms and other pipelines under development.

Zeling Biotech is a company affiliated with the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University.Founded by Professor Chen Lijuan of the laboratoryA technology-based enterprise focusing on the development of original Class 1 new drugs. According to the press release from Zeling Biotech, the company leverages the multidisciplinary research advantages of Sichuan University and West China Hospital, and collaborates with the listed company Guizhou Bailong, guided by technological innovation.Focusing on unmet clinical needs, concentrating on areas such as malignant tumors, inflammation, and autoimmune diseases, dedicated to discovering, developing, and commercializing innovative drugs that are potentially "first-in-class" and "best-in-class".

Readers, please star ⭐Chuangjianhui to receive push notifications第一时间收到推送.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized re-posting or reproduction by media or institutions in any form to other platforms is strictly prohibited. For re-posting authorization, please contact us at"InnoView"Contact us via the WeChat Official Account message.

More Data Content Recommendations

Click "InSee", Sharing New Health Trends from Creative Insights